Skip to main content
. 2020 Sep 28;10:15902. doi: 10.1038/s41598-020-72710-3

Table 3.

Clinical Outcomes at eight months.

Adverse Event rhBNP (n = 75) Control (n = 79)
no./total no.(%)
Difference (95% CI) P value
Composite endpoints 10/75 (13) 20/79 (25.3) − 12.3 (0.197–1.048) 0.061
Target-vessel revascularization 3/75 (4) 5/79 (6.3) − 2.3 (0.142—2.676) 0.72
Recurrent angina 7/75 (9) 15/79 (19) − 10 (0.168—1.147) 0.087

CI: confidence interval; rhBNP: recombinant human brain natriuretic peptide.